CAR-T cell therapy may include non-Hodgkin's lymphoma (NHL) in certain blood cancers, such as lymphoma and leukemia (lymphomas that do not improve after chemotherapy or stem cell transplantation), leukemia with chronic lymphocytic leukemia (CLL) It may include acute lymphoblastic leukemia (ALL).

In China, clinical trials have been conducted in patients with T-cell hematopoietic and lymphoma malignancies. From the viewpoint of CAR-T cells in the treatment of hematologic tumors in China and the United States, most of the CAR-T in China and USA are showing good therapeutic effect. 66.9% (China) and 68.5% (United States) respectively.​  

Five of the top five cities in the United States are Houston (48 studies), followed by Beijing (38), Shanghai (25), Chongqing (16), Guangzhou (15) , Philadelphia (34 studies), New York (16 studies), Duarte (14 studies) and Seattle (14 studies). China's CAR-T cell clinical studies are growing at a faster pace than the US.

Numerically, in 2017, China showed a 133% increase over the United States. 

On December 31, 2017, CAR-T treatment at the website clinicaltrials.gov accounted for 91.1% of CAR-T treatments worldwide, and China entered 317 clinical trials. (Other countries include the United Kingdom, Italy, Sweden, Germany, Spain, Japan, Israel and Australia, which account for less than 10% of the world's total).

HK HIS offers treatment options for US FDA approved CAR-T treatments and current clinical treatments. Please contact HK HIS.